These findings suggest a differential response pattern consistent with the outcome documented in the clinical setting where CRC patient derived tumors with KRAS genes that are non-mutated in codons 12/13, 61 and 146 do not always respond to anti-EGFR agents (Supplementary Fig. S1A–D)15. Here, KRAS is linked to colorectal carcinoma.